The China bioprocess instruments market size was estimated at USD 1.18 billion in 2016 and is expected to grow on account of the evolution of new technologies. An ageing population and increasing occurrences of lifestyle related illnesses among youth are expected to augment the growth of the healthcare sector in the country over the next few years.
China bioprocess instruments market revenue, 2014 - 2024 (USD Billion)
The government of China has been focusing on biopharmaceuticals and is undertaking initiatives to enhance pharmaceutical innovation to pursue its goal of becoming an emerging biosimilar development hub. Additionally, the government of China has been supporting the bioprocessing industry by providing various grants and subsidies to the manufacturers to take on R&D activities in the biopharmaceutical industry.
Bioprocessing instruments are used in pharmaceutical, biopharmaceutical industry, R&D labs and medical laboratories. Rapid development and increased life science research in biopharmaceuticals and bioprocessing market in China is expected to have the significant contribution to the growth of the market over the forecast period.
With a population of 1.38 billion people and the second largest GDP in the world, China became the second largest pharmaceutical market in 2016. Increasing use of bioprocess instruments in pharmaceuticals is expected to propel the growth of the market. These devices are used for measurement of xenobiotics and biotics such as macromolecules, DNA and proteins in the biological system.
An increasing prevalence of chronic diseases such as cardiovascular, diabetes, oncology, HIV/AIDS, multiple sclerosis, and arthritis is expected to increase the demand for biologics medicine. The industry is anticipated to experience further commercialization to serve ageing population in China. The ageing population will generate higher demand for health care services, since elderly groups have weaker immune systems, resulting in a higher incidence of illness.
The high cost of instruments and rigorous regulatory policies imposed by the government of China are projected to hinder the growth of the industry. Moreover, shortage of skilled labour is another challenge in the growth of bioprocessing industry, as bioprocessing industry has a different level of products, and each needs different expertise to manufacture it.
Segmentation by Typ e
• Cell Expansion
• Flow Cytometry
• Biologics Safety Testing
• Cell Line Development
• Tangential Flow Filtration
• Cell Counter
• Virus Filtration
• Cell Culture
• Pyrogen Testing
• Single-Use Bioprocessing
In terms of type, cell culture segment dominated the bioprocess instruments industry in 2016 accounting for 23% of the revenue share. However, the segment is anticipated to lose its market share over the forecast period, on account of their rising demand for other instruments such as biological safety testing and cell expansion due to their significantly lower cost of production and technological advancement.
However, due to less stringent regulatory norms and low labour cost the market would still witness a steady growth for the forecast period until other instruments are adapted completely. Owing to these profits, the development of biopharmaceutical drug in China is on the increase on accounts of high investments by several pharmaceutical giants.
The single use bioprocessing market in China was valued at USD 163.4 million in 2016. In June 2016, WuXi Biologics along with Sartorius Stedim Biotech opened a joint laboratory which is equipped with single-use bioprocessing equipment. The year 2016 also saw two foreign companies, JHL Biotech (Taiwan) and GE (U.S.), opening an fully functional single-use bioprocessing facility in China.
Pyrogen testing market is the fastest growing market at a 14.4% CAGR over the forecast period. Increasing demand for this testing technique to reduce the occurrence of fever induced post injecting a vaccine is expected to augment the growth of the market. The growth of the biopharmaceutical industry is expected to result in the high demand of this technique over the forecast period.
Cell line development market is expected to witness at a double-digit CAGR over the forecast period. Cell line development has been increasing on account of rising demand for vaccine production, monoclonal antibodies, and use of pioneering technologies to develop cell lines.
Some of the prominent market players in the industry include Abbott, PerkinElmer, Inc., and Thermo Fisher Scientific Inc. Some of the other vendors active in the China bioprocess instruments industry are Bailun Biotechnology, Daysly Machinery, Ritai, Pharmao Industries Co., Ltd, GE Healthcare, Oxford MEStar Ltd, JHL Biotech, and Merck & Co.
Research Support Specialist, USA